Home » Stocks » BYSI

BeyondSpring, Inc. (BYSI)

Stock Price: $12.88 USD -0.07 (-0.54%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $12.57 -0.31 (-2.41%) Jan 15, 6:51 PM
Market Cap 504.14M
Revenue (ttm) n/a
Net Income (ttm) -38.09M
Shares Out 24.65M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $12.88
Previous Close $12.95
Change ($) -0.07
Change (%) -0.54%
Day's Open 12.85
Day's Range 12.54 - 13.26
Day's Volume 328,300
52-Week Range 9.68 - 18.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th...

GlobeNewsWire - 2 weeks ago

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th...

Seeking Alpha - 1 month ago

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.

GlobeNewsWire - 1 month ago

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone

Insider Monkey - 1 month ago

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncol...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative canc...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative canc...

GlobeNewsWire - 2 months ago

- Announced SEED Therapeutics Inc.(“SEED”)'s collaboration with Eli Lilly and Company(“Lilly”)

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncol...

GlobeNewsWire - 2 months ago

- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines -

GlobeNewsWire - 3 months ago

Former Forty Seven and Roche Senior Executives to Support Partnering Efforts Former Forty Seven and Roche Senior Executives to Support Partnering Efforts

GlobeNewsWire - 3 months ago

NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-...

GlobeNewsWire - 3 months ago

Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain P...

GlobeNewsWire - 3 months ago

New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-on...

Zacks Investment Research - 4 months ago

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Pr...

Seeking Alpha - 4 months ago

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative ca...

Seeking Alpha - 4 months ago

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: GTHX, KPTI, URGN
Seeking Alpha - 4 months ago

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: GTHX, KPTI, URGN
GlobeNewsWire - 4 months ago

Gilead Acquired Forty Seven in March 2020 for $4.9 Billion Gilead Acquired Forty Seven in March 2020 for $4.9 Billion

Seeking Alpha - 5 months ago

BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster

GlobeNewsWire - 5 months ago

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

GlobeNewsWire - 6 months ago

Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 Data Presented Shows Plinabulin Mobilizes Bone Marr...

Zacks Investment Research - 6 months ago

BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

The Motley Fool - 6 months ago

The company announced the pricing of a public offering of common stock.

GlobeNewsWire - 7 months ago

-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p

GlobeNewsWire - 7 months ago

- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN -

GlobeNewsWire - 7 months ago

- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone -

GlobeNewsWire - 7 months ago

- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC -

GlobeNewsWire - 8 months ago

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno...

Seeking Alpha - 8 months ago

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative c...

GlobeNewsWire - 8 months ago

The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years The Potential f...

GlobeNewsWire - 9 months ago

- Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years -

GlobeNewsWire - 10 months ago

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative...

InvestorPlace - 10 months ago

No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on ...

Other stocks mentioned: EQT, ESTE, EVFM, MSON, PLYA, SQNS
GlobeNewsWire - 11 months ago

Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabulin as a Potent activator of the Innate Immune System Presentation at the 2020 ASCO-SITC Provides Strong Validation for...

GlobeNewsWire - 11 months ago

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative ...

GlobeNewsWire - 1 year ago

Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention Plinabulin Protects Bone Marrow from Chemot...

Seeking Alpha - 1 year ago

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 Premature Patient Drop-Out Rate from Comparator Arm Might Contribute...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, ...

Seeking Alpha - 1 year ago

The stock is down due to the recent share offering done at a 20% discount to market price.

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development a...

About BYSI

BeyondSpring, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a p... [Read more...]

Industry
Biotechnology
IPO Date
Mar 9, 2017
CEO
Dr. Lan Huang
Employees
61
Stock Exchange
NASDAQ
Ticker Symbol
BYSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BeyondSpring stock is "Strong Buy." The 12-month stock price forecast is 32.83, which is an increase of 154.89% from the latest price.

Price Target
$32.83
(154.89% upside)
Analyst Consensus: Strong Buy